Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir added to remdesivir for adults with COVID-19
IRCT20150107020592N31Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of molnupiravir and remdesivir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Improve oxygenation, Improve CT scans and 1 more. Started Dec 2021; status: completed.
02
Drugs
molnupiravirremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150107020592N31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150107020592N31.